Content Quality: Well-organized News piece (732 words, within the 400-1200 range) with clear Overview / What We Know / Human Trials Already Underway / What We Don't Know structure. The 'What We Don't Know' closer is a genuine editorial strength: it explicitly states the primate study does not establish protection from infection in animals or people, and it correctly separates 'individual immunogen components tested in humans' from 'the complete prime-and-boost regimen tested in primates, not yet tried in people.' This directly answers the assignment's core scrutiny point (primate result vs. eventual human efficacy) and the article does not overstate it anywhere I could find.
Source Verification: Read all 4 source snapshots from disk (gunzip + full-text extraction), decompressed to /private/tmp scratchpad for review. (1) sources/2026-07/.../source-0.html.gz (nature.com, 3038 bytes) — this snapshot is NOT usable: it is a JS 'Client Challenge' bot-block page (redirected_domain: idp.nature.com per manifest.json), containing zero article content. Per the skill's fallback rule I attempted a live WebFetch of the same Nature URL as a last resort; it hit the identical idp.nature.com authorize redirect chain live, confirming the snapshot failure was a genuine site-side auth/bot-wall and not a fetch artifact. Following the redirect chain through to the article page, WebFetch returned the abstract with figures matching the article's quotes verbatim: 'serum bnAb activity developed in 44% of animals', 'bnAb lineages were generated in ≥50% of animals', and 'up to 67% neutralization breadth compared to the reference bnAb' (confirms title figure, the >=50% figure, and substance of the 67% figure — note the article's quoted fragment '67% compared to the reference bnAb' drops the words 'neutralization breadth' from the middle of that quotation without an ellipsis; a minor quoting-precision issue, not a fabrication, since the underlying 67% figure and its meaning are accurate). Publication date '30 June 2026' and paper title 'Vaccination elicits HIV broadly neutralizing antibodies in primates' also confirmed via this live fetch, matching the article. (2) source-1.html.gz (lji.org, 213KB) — read in full as extracted plain text. Confirms: the 44% figure ('around 44 percent of the animals went on to produce broadly neutralizing antibodies against HIV in their blood'), the germline-targeting definition quote, the priming/shepherding-booster staging quotes, both Crotty quotes verbatim ('This feels like a huge success' and 'We succeeded in taking ultra-rare antibody responses...'), Crotty's and Schief's titles, Madden/Steichen co-first-author credit and affiliations, Emory National Primate Research Center and rhesus macaques, and the HVTN 144 / IAVI G004 human-trial-status sentence verbatim. (3) source-2.html.gz (news-medical.net, 180KB) — read in full; this outlet republishes the LJI release near-verbatim (confirmed same journal reference: Steichen et al., Nature, DOI 10.1038/s41586-026-10837-5, matching the submission's Nature URL) and independently confirms the mutation-diversity Madden quote and the 'IAVI, Scripps Research, the HIV Vaccine Trials Network, and partners are now advancing plans...' sentence the article attributes to News-Medical. (4) source-3.html.gz (iavi.org, 193KB) — read in full; confirms the three immunogen names (eOD-GT8 60mer, Core-g28v2 60mer, N332-GT5 gp151), Moderna mRNA delivery, 96 participants across six South African sites, the G001/G002/G003 sentence verbatim, and both the Feinberg and Schief quotes verbatim. However, this snapshot surfaced a factual problem: the press release states first doses were administered 'on December 15, 2025... initiating the IAVI G004 clinical trial' and the release itself is dated January 6, 2026. The article states the trial 'IAVI announced began dosing participants in January 2026' — this conflates the January 2026 announcement/press-release date with the actual dosing start date, which was December 2025. This is a specific, verifiable date error in a subordinate body claim (not the headline/summary/lead).
Factual Accuracy: All specifics I could verify trace correctly to their cited sources, with one exception: the dosing-start date for IAVI G004 is wrong by about three weeks and the wrong year is implied ('January 2026' vs. actual December 15, 2025). Every direct quote inside quotation marks is verbatim in its cited snapshot except the truncated Nature '67%' fragment noted above. No hallucinated names, titles, or figures found. Title/summary/lead (the 44% figure and the vaccine's basic description) are all solidly sourced across three independent documents (Nature abstract itself, LJI, News-Medical), so this is not a headline/lead problem.
Overall Assessment: Substantively strong, well-sourced science News piece with an unusually careful primate-vs-human-efficacy caveat. One subordinate factual error (IAVI G004 dosing month/year) is real and specific but isolated and fully recoverable with a single corrections note; it does not touch the headline, summary, or lead. APPROVE_WITH_CORRECTIONS.